Copyright Reports & Markets. All rights reserved.

Dynamics in Post-pandemic Global Primary Biliary Cholangitis Treatment Industry: Supply and Demand, Markets and Prices 2021-2027

Request for Sample of this report
Buy now

Table of Contents

    1 Product Introduction and Overview

    • 1.1 Product Definition
    • 1.2 Product Specification
    • 1.3 Global Market Overview
      • 1.3.1 Global Primary Biliary Cholangitis Treatment Market Status and Forecast (2016-2027)
      • 1.3.2 Global Primary Biliary Cholangitis Treatment Sales Value CAGR by Region
    • 1.4 Market Drivers, Inhibitors
      • 1.4.1 Market Drivers
      • 1.4.2 Market Inhibitors
      • 1.4.3 COVID-19 Impact Analysis

    2 Global Primary Biliary Cholangitis Treatment Supply by Company

    • 2.1 Global Primary Biliary Cholangitis Treatment Sales Value by Company
    • 2.2 Primary Biliary Cholangitis Treatment Sales Area of Main Manufacturers
    • 2.3 Trend of Concentration Rate

    3 Global and Regional Primary Biliary Cholangitis Treatment Market Status by Category

    • 3.1 Primary Biliary Cholangitis Treatment Category Introduction
      • 3.1.1 Ursodeoxycholic Acid (UDCA)
      • 3.1.2 Obeticholic Acid (Ocaliva)
    • 3.2 Global Primary Biliary Cholangitis Treatment Market by Category
    • 3.3 North America: by Category
    • 3.4 Europe: by Category
    • 3.5 Asia Pacific: by Category
    • 3.6 Central & South America: by Category
    • 3.7 Middle East & Africa: by Category

    4 Global and Regional Primary Biliary Cholangitis Treatment Market Status by End User/Segment

    • 4.1 Primary Biliary Cholangitis Treatment Segment by End User/Segment
      • 4.1.1 Hospitals
      • 4.1.2 Clinics
      • 4.1.3 Others
    • 4.2 Global Primary Biliary Cholangitis Treatment Market by End User/Segment
    • 4.3 North America: by End User/Segment
    • 4.4 Europe: by End User/Segment
    • 4.5 Asia Pacific: by End User/Segment
    • 4.6 Central & South America: by End User/Segment
    • 4.7 Middle East & Africa: by End User/Segment

    5 Global Primary Biliary Cholangitis Treatment Market Status by Region

    • 5.1 Global Primary Biliary Cholangitis Treatment Market by Region
    • 5.2 North America Primary Biliary Cholangitis Treatment Market Status
    • 5.3 Europe Primary Biliary Cholangitis Treatment Market Status
    • 5.4 Asia Pacific Primary Biliary Cholangitis Treatment Market Status
    • 5.5 Central & South America Primary Biliary Cholangitis Treatment Market Status
    • 5.6 Middle East & Africa Primary Biliary Cholangitis Treatment Market Status

    6 North America Primary Biliary Cholangitis Treatment Market Status

    • 6.1 North America Primary Biliary Cholangitis Treatment Market by Country
    • 6.2 United States
    • 6.3 Canada
    • 6.4 Mexico

    7 Europe Primary Biliary Cholangitis Treatment Market Status

    • 7.1 Europe Primary Biliary Cholangitis Treatment Market by Country
    • 7.2 Germany
    • 7.3 France
    • 7.4 UK
    • 7.5 Italy
    • 7.6 Russia
    • 7.7 Spain

    8 Asia Pacific Primary Biliary Cholangitis Treatment Market Status

    • 8.1 Asia Pacific Primary Biliary Cholangitis Treatment Market by Country
    • 8.2 China
    • 8.3 Japan
    • 8.4 Korea
    • 8.5 Southeast Asia
    • 8.6 India
    • 8.7 Australasia

    9 Central & South America Primary Biliary Cholangitis Treatment Market Status

    • 9.1 Central & South America Primary Biliary Cholangitis Treatment Market by Country
    • 9.2 Brazil
    • 9.3 Argentina
    • 9.4 Colombia

    10 Middle East & Africa Primary Biliary Cholangitis Treatment Market Status

    • 10.1 Middle East & Africa Primary Biliary Cholangitis Treatment Market by Country
    • 10.2 Iran
    • 10.3 Israel
    • 10.4 Turkey
    • 10.5 South Africa
    • 10.8 Saudi Arabia

    11 Major Downstream Customers Analysis

    • 11.1 Customer One Analysis
    • 11.2 Customer Two Analysis
    • 11.3 Customer Three Analysis
    • 11.4 Customer Four Analysis

    12 Global Primary Biliary Cholangitis Treatment Market Forecast by Category and by End User/Segment

    • 12.1 Global Primary Biliary Cholangitis Treatment Sales Value Forecast (2022-2027)
    • 12.2 Global Primary Biliary Cholangitis Treatment Forecast by Category
    • 12.3 Global Primary Biliary Cholangitis Treatment Forecast by End User/Segment

    13 Global Primary Biliary Cholangitis Treatment Market Forecast by Region/Country

    • 13.1 Global Primary Biliary Cholangitis Treatment Market Forecast by Region (2022-2027)
    • 13.2 North America Market Forecast
    • 13.3 Europe Market Forecast
    • 13.4 Asia Pacific Market Forecast
    • 13.5 Central & South America Market Forecast
    • 13.6 Middle East & Africa Market Forecast

    14 Key Participants Company Information

    • 14.1 Teva Pharmaceutical
      • 14.1.1 Company Information
      • 14.1.2 Primary Biliary Cholangitis Treatment Product Introduction
      • 14.1.3 Teva Pharmaceutical Primary Biliary Cholangitis Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.1.4 SWOT Analysis
    • 14.2 Retrophin
      • 14.2.1 Company Information
      • 14.2.2 Primary Biliary Cholangitis Treatment Product Introduction
      • 14.2.3 Retrophin Primary Biliary Cholangitis Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.2.4 SWOT Analysis
    • 14.3 Pfizer
      • 14.3.1 Company Information
      • 14.3.2 Primary Biliary Cholangitis Treatment Product Introduction
      • 14.3.3 Pfizer Primary Biliary Cholangitis Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.3.4 SWOT Analysis
    • 14.4 Novartis
      • 14.4.1 Company Information
      • 14.4.2 Primary Biliary Cholangitis Treatment Product Introduction
      • 14.4.3 Novartis Primary Biliary Cholangitis Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.4.4 SWOT Analysis
    • 14.5 Lumena Pharmaceuticals
      • 14.5.1 Company Information
      • 14.5.2 Primary Biliary Cholangitis Treatment Product Introduction
      • 14.5.3 Lumena Pharmaceuticals Primary Biliary Cholangitis Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.5.4 SWOT Analysis
    • 14.6 Intercept Pharmaceuticals
      • 14.6.1 Company Information
      • 14.6.2 Primary Biliary Cholangitis Treatment Product Introduction
      • 14.6.3 Intercept Pharmaceuticals Primary Biliary Cholangitis Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.6.4 SWOT Analysis
    • 14.7 GlaxoSmithKline
      • 14.7.1 Company Information
      • 14.7.2 Primary Biliary Cholangitis Treatment Product Introduction
      • 14.7.3 GlaxoSmithKline Primary Biliary Cholangitis Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.7.4 SWOT Analysis
    • 14.8 Bristol-Myers Squibb
      • 14.8.1 Company Information
      • 14.8.2 Primary Biliary Cholangitis Treatment Product Introduction
      • 14.8.3 Bristol-Myers Squibb Primary Biliary Cholangitis Treatment Sales Value, Gross Margin and Global Share (2019-2021)
      • 14.8.4 SWOT Analysis

    15 Conclusion

      16 Methodology

      Covid-19 has impacted the supply and demand status for many industries along the supply chain. In this report a comprehensive analysis of current global Primary Biliary Cholangitis Treatment market in terms of demand and supply environment is provided, as well as price trend currently and in the next few years. Global leading players are profiled with their revenue, market share, profit margin, major product portfolio and SWOT analysis. This report also includes global and regional market size and forecast, major product development trend and typical downstream segment scenario, under the context of market drivers and inhibitors analysis. According to this survey, the global Primary Biliary Cholangitis Treatment market is estimated to have reached $ xx million in 2020, and projected to grow at a CAGR of xx% to $ xx million in 2027.

      Segmented by Category
      Ursodeoxycholic Acid (UDCA)
      Obeticholic Acid (Ocaliva)

      Segmented by End User/Segment
      Hospitals
      Clinics
      Others

      Segmented by Country
      North America
      United States
      Canada
      Mexico
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Asia Pacific
      China
      Japan
      Korea
      Southeast Asia
      India
      Australasia
      Central & South America
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Iran
      Israel
      Turkey
      South Africa
      Saudi Arabia

      Key manufacturers included in this survey
      Teva Pharmaceutical
      Retrophin
      Pfizer
      Novartis
      Lumena Pharmaceuticals
      Intercept Pharmaceuticals
      GlaxoSmithKline
      Bristol-Myers Squibb
      Buy now